February 25, 2015. Release of updated plugin Shannon splicing mutation pipeline software for Qiagen-CLC bio products
Cytognomix has released version 2.0.2 of the Shannon splicing mutation pipeline for the Qiagen-CLCbio Genomics Workbench versions 7.5.2 and 8.0 and for Genomics Server versions 6.5.3 and 7.0. Please contact Qiagen-CLCbio to purchase a license to this software.
Cytognomix is pleased to announce the sale of annual subscriptions of our MutationForecaster system to a molecular diagnostics laboratory at a public hospital in the Toronto metropolitan area in Ontario, Canada. The client is a long time paid subscriber of our ASSEDA product, who now has an express need for higher throughput software to handle results of next generation sequencing studies. MutationForecaster™ is the only efficient and accurate platform for comprehensive, on-demand coding and mRNA splicing mutation analysis on the market.
We find and validate mutations that others cannot.
Contact us or register at mutationforecaster.com.
MutationForecaster is our new, comprehensive genome interpretation suite to interpret and validate mutations that affect mRNA splicing and protein coding. Our products can find and validate mutations that others cannot.
(Click any of the images below to view the paper)
MutationForecaster brings together our world class software in a single easy-to-use interface:
- The popular Automated Splice Site and Exon Definition server (ASSEDA)
- The Shannon pipeline for genome scale mRNA splicing mutation analysis
- Veridical, the first solution for validating splicing mutations by RNASeq
- Variant Effect Predictor for identification of coding changes and predicting their impact
- Cytognomix User Variation Database, to store and compare results obtained with these tools with other sources of genomic variation
- Our Visual analytics Decision Support Tool, for cytogenomic interpretation, and single copy hybridization genomic reagent design
We will be announcing our new MutationForecaster system imminently.
You can register now for a subscription. Sign up!
Veridical is now hosted by Cytognomix. The previous Veridical.org website has been migrated to Veridical.cytognomix.com.
This software product has been integrated into our new MutationForecaster webservice. To validate splicing mutations predicted by the Shannon pipeline, a set of gene variants (in vcf format) and RNASeq data (in bam format) are uploaded for the same individual. Control data are built in, the analysis is automated, and results are returned directly to users. Subscriptions to MutationForecaster will be available from Cytognomix in early 2015.
The standalone software is also available from Cytognomix, which licenses it and provides installation support. To further inquire, contact us at email@example.com.
We have published a new manuscript which has implications for metaphase chromosome epigenetics. The citation is:
Title: Localized, non-random differences in chromatin accessibility between homologous metaphase chromosomes
Authors: Khan A Wahab, Rogan K Peter, Knoll Joan,
Journal: Molecular Cytogenetics.2014, 7:70
We have published a review of the literature on information theory-based splicing mutations. The review includes a large dataset, comprehensive bibliography, and new software – the Splicing Mutation Calculator – for determining the impact of mutations at natural splice sites, based on the published literature. There are multiple citations of this work -
for the Review paper: Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis [v1; ref status: awaiting peer review, http://f1000r.es/4nq] (doi: 10.12688/f1000research.5654.1), 2014.
for the Dataset: F1000Research: Dataset 1. Dataset for mRNA splicing mutations in genetic disease, (doi: 10.5256/f1000research.5654.d382482)
Cytognomix’s technology key to new publication on origin of metastasis in breast cancer:
Dorman S, Viner C, Rogan PK. Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer, Nature Scientific Reports, 4: 7063 (DOI: 10.1038/srep07063), 2014.
Using our patented ab initio scFISH probes, Cytognomix and Western University researchers have discovered important differences between paired chromosomes. No other product on the market can detect these chromosome features. The following article has been accepted for publication in a leading open access journal:
Khan W, Rogan PK, and Knoll JHM. Localized, Non-random Differences in Chromatin Accessibility between Homologous Metaphase Chromosomes, Mol. Cytogenetics, in press.
Stay tuned for the URL of the published paper. It should be available shortly!
Peter Rogan gave an invited presentation titled: ”Interpreting pathogenic human genome variation: methods, applications and implications,” at the Patent Examiner Technical Training Program at the US Patent and Trademark Office. The presentation was webcasted to all USPTO offices across the United States. The program is focused on providing technical training to Patent Examiners, in this case to the Patent Examiners of Technology Center 1600 that examines patent applications on various aspects of biotechnology inventions.
The patent office recognized his contribution: link
US Pat. App. No. 13/744459 has been published by the US Patent and Trademark Office.
The invention is entitled: Stable gene targets in breast cancer and use thereof for optimizing therapy.
|Inventors||Peter Keith Rogan, Joan Helen Knoll|
Peter Rogan, President of Cytognomix has been invited by Oxford Global to present at the 6th Annual Next Generation Sequencing Congress at the Queen Elizabeth II Conference Center in London, UK on Nov. 21, 2014. The oral presentation is titled: “Impact Of Non-coding Mutation Analysis In Hereditary and Somatic Breast Cancer.” In the talk, Dr. Rogan will showcase results of the use of Cytognomix’s software and genomic reagents to obtain new insights into the genomic abnormalities present in breast cancer.
US Pat. Application No. 14/154,905 describes our method of predicting cryptic and exon skipping isoforms in mRNA produced by splicing mutations from the combined information contents and the distribution of the splice sites and other regulatory binding sites defining these exons. Results obtained are highly concordant with result of expression studies. A paper has been published in Human Mutation
Cytognomix will be presenting several papers at the upcoming ASHG annual meeting (October 18-22, 2014, San Diego):
Using information theory to analyze and predict splicing mutations in rare and common diseases: performance and best practices. N.G. Caminsky, E. Mucaki and P.K. Rogan
Reversing differences in chromatin accessibility that distinguish homologous mitotic metaphase chromosomes. W.A. Khan, P.K. Rogan, J.H.M. Knoll
Automated Dicentric Chromosome Identification by Machine Learning-based Image Processing. P.K. Rogan, Y. Li, A. Subasinghe, J. Samarabandu, R. Wilkins and J.H. Knoll
Towards the minimal breast cancer genome and its relevance to chemotherapy. S.N. Dorman, J.H. Knoll, K. Baranova, C. Viner, P.K. Rogan
The FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping and is a risk factor for familial breast cancer. Paolo Peterlongo , Francesca Damiola, Eliseos Mucaki, Valentina Dall’Olio ,Sara Pizzamiglio , Irene Catucci , Anders Kvist , Paolo Verderio, Mara Colombo , Loris Bernard , Hans Ehrencrona, Laura Caleca, Valeria Pensotti , Sylvie Mazoyer, Peter K. Rogan ,Paolo Radice
Please contact us if you would like to meet or discuss this work.